J Rheumatol. 2023;50(8):1020–1028 doi: 10.3899/jrheum.221022
Three-year data from the ixekizumab (IXE) COAST programme provide additional evidence that patients with axSpA receiving IXE experience long-term safety, and sustained improvements in efficacy outcomes, at 3 years.
Determining the safety profile of a biologic from multiple studies and long-term extension studies is of the utmost importance for patients receiving longstanding treatment. To this end, Deodhar, et al. assessed the safety and efficacy of IXE treatment in patients with r-axSpA and nr-axSpA for up to 156 weeks.